October 9, 2013
Chemo-Sero-Therapeutic Research Institute, or Kaketsuken, filed a new drug application on October 7 for a bypassing product for managing hemostasis in hemophilia patients with inhibitors (activated factor VII/factor X mixture agent), which would be the first domestically produced hemophilia inhibitor...read more